With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …

Evidence is strengthening for the morphological evaluation of tumor infiltrating lymphocytes
(TILs) in breast cancer. Herein, the concepts for TILs assessment are laid out by pathologists …

Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer
strategy. Several lines of evidence support the study of immunotherapy in triple-negative …

T cell–mediated immunotherapies are promising cancer treatments. However, most patients
still fail to respond to these therapies. The molecular determinants of immune resistance are …

Background Treatment options for previously treated metastatic triple-negative breast cancer
(mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated …

Overexpression of the B7-H1 (PD-L1) molecule in the tumor microenvironment (TME) is a
major immune evasion mechanism in some patients with cancer, and antibody blockade of …

Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have
shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this …

Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic
strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 …

Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to
chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple …